In the study by Levine et al. (2019), detailed reports of adverse events were provided, with 12 cases in the PEN+CDED group (including transient ALT elevation, viral infection, hospitalization-fever and gastroenteritis, flare, hospitalization flare, elevated amylase/lipase, upper respiratory infection, hypophosphatemia, herpes zoster, acute gastroenteritis, drug-induced emesis, hematemesis) and 13 cases in the EEN group (including transient ALT elevation, exacerbation, Nausea, flare, hospitalization flare, diarrhea, cough, skin abscess, headache). This evidence concerns the gene GPT and Hematemesis.